Home > Inhibitors & Agonists > Ras-Raf-MAPK-ERK > MEKK (MAP3K)
Cat. No. Product name CAS No.
DC11622 MAP3K14-IN-173

A novel potent MAP3K14 kinase inhibitor with IC50 of 1.8 nM (NIK autophosphorylation).

DC11610 AKS1-IN-19

A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3.

DC11558 DLK-IN-14

A potent, selective, CNS penetrant dual leucine zipper kinase (DLK, MAP3K12) inhibitor with Ki of 3 nM.

DC10781 ASK1-IN-1 Featured

ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4.

DC9555 Cot inhibitor-2

Cot inhibitor-2 is a COT/Tpl2 inhibitor.

DC10106 GNE-3511 Featured

GNE-3511 is a potent and selective zipper kinase (DLK, MAP3K12) inhibitors.

DC8787 NQDI-1 Featured

NQDI-1 is a specific inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM) that demonstrates potent selectivity against various serine/threonine and tyrosine protein kinases.

DC11036 TCASK10

TCASK10 is a potent, highly specific inhibitor of ASK1 with IC50 of 14 nM, 30-fold selectivity over ASK2 (IC50=510 nM) and no activity against MEKK1, TAK1, IKKβ, ERK1, JNK1, p38α, GSK-3β, PKCθ and B-raf.

DC9873 Selonsertib(GS-4997) Featured

Selonsertib(GS-4997)is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.

DC44947 SM1-71

SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.

DC47890 TAK1-IN-3

TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.

DC70429 GDC-0134

GDC-0134 (GDC0134) is a potent, selective, orally available, brain-penetrant inhibitor of dual leucine zipper kinase (DLK, MAP3K12).GDC‐0134 blocks DLK activity in cellular assays and in animal models of neuronal injury.Dual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS).

Page 1 / Total 1 FirstPrevNextLastGoto